CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
Lumasirandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04152200
NCT04152200Phase 3Completed
CompareCT.gov

ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals·interventional·Posted Nov 5, 2019·Updated Jul 18, 2025

In Brief

A Phase 3 clinical trial evaluating Lumasiran for Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria. Completed, enrolled 21 participants across 14 sites in 11 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hyperoxaluria Type 1, Primary Hyperoxaluria
CountriesAustralia, Belgium, France, Israel, Italy, Jordan, Lebanon, Netherlands, Turkey (Türkiye), United Arab Emirates, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedNov 5, 2019
Enrollment StartJan 21, 2020
Primary CompletionMay 18, 2021
Study CompletionJun 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.7 years ago

Interventions

Lumasirandrug

Lumasiran will be administered by subcutaneous (SC) injection.